Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
Founded
2011
Raised
$98.1M
Follow us
Alexa global traffic share
Twitter followers
06 Nov 2014
$26,000,000
Venture capital (Series B)
18 Dec 2012
$6,564,102
Venture capital